CLDX – celldex therapeutics, inc. (US:NASDAQ)
Stock Stats
News
3/2
12:36 pm
cldx
Low
Celldex Therapeutics (CLDX) had its price target raised by The Goldman Sachs Group, Inc. from $30.00 to $34.00. They now have a "neutral" rating on the stock.
3/1
10:14 am
cldx
Low
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
3/1
09:45 am
cldx
Low
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
2/28
01:37 pm
cldx
Low
Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory [Yahoo! Finance]
2/27
09:42 pm
cldx
Low
Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential [Yahoo! Finance]
2/25/2026
04:01 pm
CLDX
-0.6%
MISS
11/10/2025
04:01 pm
CLDX
7.5%
MISS
5/8/2025
04:01 pm
CLDX
-6.1%
MISS
3/2
12:10 pm
Maintains
Neutral
Neutral
Goldman Sachs
Low
-0.2%
3/2
12:10 pm
Maintains
Neutral
Neutral
Goldman Sachs
Low
-0.2%
3/2
12:10 pm
Maintains
Neutral
Neutral
Goldman Sachs
Low
-0.2%
2/26
09:26 am
Reiterates
Buy
Buy
Stifel Nicolaus
Medium
3.6%
2/26
09:26 am
Reiterates
Buy
Buy
Stifel Nicolaus
Medium
3.6%
2/25
04:08 pm
cldx
Low
Form 10-K Celldex Therapeutics, For: Dec 31
2/25
04:01 pm
cldx
Low
Form 8-K Celldex Therapeutics, For: Feb 25
2/10
11:22 am
cldx
Low
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP
2/9
06:26 am
cldx
Medium
Form SCHEDULE 13G Celldex Therapeutics, Filed by: STATE STREET CORP
1/6
04:24 pm
cldx
Medium
Form 4 Celldex Therapeutics, For: Jan 02 Filed by: Martin Samuel Bates
Show more
Top News Gainers
2/20 Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. 30.1%
4/28 Form DEF 14A Celldex Therapeutics, For: Jun 18 9.6%
3/26 Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus N/A ActVsEst N/A - N/A 3.4%
8/7 Q2/2019 6/30/2019 EPS -0.840 ZacksConsensus -1.170 ActVsEst 0.330 - Beat 2.3%
6/21 Form S-8 Celldex Therapeutics, 2.0%
10/2 Celldex Therapeutics Announces Upcoming Data Presentations 1.9%
10/9 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 1.4%
12/23 Is Celldex Therapeutics, Inc. (CLDX) A Good Stock To Buy? [Yahoo! Finance News] 1.3%
2/12 Form SC 13G Celldex Therapeutics, Filed by: RENAISSANCE TECHNOLOGIES LLC 0.4%
5/24 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 0.4%
Top News Decliners
3/27 Form 424B5 Celldex Therapeutics, -12.3%
6/1 Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma -9.6%
11/8 CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study -9.2%
12/6 Form S-3 Celldex Therapeutics, -9.1%
11/12 Q3/2019 9/30/2019 EPS -0.750 ZacksConsensus -0.840 ActVsEst 0.090 - Beat -7.3%
11/18 Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159 -5.9%
3/3 Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program -4.6%
5/7 Q1/2019 3/31/2019 EPS -1.400 ZacksConsensus -1.140 ActVsEst (0.260) - Miss -3.6%
5/8 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was given a new $19.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -2.8%
7/31 Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call -2.8%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3